Analysis the causes of ureteral stent encrustation and comparison of composition of encrustation and original stone

doi:10.3877/cma.j.issn.1674-3253.2022.03.006

Abstract

Abstract:

Objective

To investigate the causes and prevention of encrustation formation of ureteral stent and compare the encrustation and original stone components.

Methods

The data of 80 patients with urinary calculi in our hospital from March 2020 to August 2021 and their primary calculi and ureteral stents with encrustation were collected. The data of 80 patients with urinary calculi without encrustation on ureteral stent were statistically analyzed. The composition of stones and encrustations were analyzed using infrared spectroscopy analysis system.

Results

There was no significant difference in sex ratio, age, creatinine, glomerular filtration rate, hydronephrosis, preoperative infection control and postoperative oral antibiotic time between the two groups (P>0.05). The patients in encrustation group got more prone to low lumbago and hematuria (P<0.05). Compared with the non encrustation group, the patients in the encrustation group had higher incidence of metabolic syndrome, lower stone clearance rate, higher urinary pH, more meat eating and tea drinking (P<0.05). 71.25%(57/80) patients had the same encrustations composition as the original stone, 28.75%(23/80) patients had inconsistent stone composition, which may be related to poor infection control and metabolic diseases.

Conclusions

The complication of ureteral stent encrustation needs to be paid enough attention. Most of the encrustation are the same as the original stones. It can be prevented by changing living habits, controlling extubation time, actively controlling urinary tract infection and treating metabolic diseases.

Key words: Ureteral stent, Encrustation, Urolithiasis, Stone composition, Infrared spectroscopy

Yuexian Xu, Guoxiang Li, Zongyao Hao. Analysis the causes of ureteral stent encrustation and comparison of composition of encrustation and original stone[J]. Chinese Journal of Endourology(Electronic Edition), 2022, 16(03): 219-223.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2022.03.006

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2022/V16/I03/219

Figures/Tables 3

References 28

[1]	Zhao J, Cao Z, Ren L, et al. A novel ureteral stent material with antibacterial and reducing encrustation properties[J]. Mater Sci Eng C Mater Biol Appl, 2016, 68: 221-228.
[2]	中华医学会糖尿病学分会代谢综合征研究协作组. 中华医学会糖尿病学分会关于代谢综合征的建议[J]. 中国糖尿病杂志, 2004, 12(3): 156-161.
[3]	Hao P, Li W, Song C, et al. Clinical evaluation of double-pigtail stent in patients with upper urinary tract diseases: report of 2 685 cases[J]. J Endourol, 2008, 22(1): 65-70.
[4]	El Faqih SR, Shamsuddin AB, Chakrabarti A, et al. Polyurethane internal stents in treatment of stone patients:morbidity related to indwelling times[J]. J Urol, 1991, 146(6): 1487-1491.
[5]	Kawahara T, Ito H, Terao H, et al. Ureteral stent encrustation, incrustation, and coloring: morbidity related to indwelling times[J]. J Endourol, 2012, 26(2):178-182.
[6]	Ather MH, Talati J, Biyabani R. Physician responsibility for removal of implants: the case for a computerized program for tracking overdue double-J stents[J]. Tech Urol, 2000, 6(3): 189-192.
[7]	Tenke P, Köves B, Nagy K, et al. Update on biofilm infections in the urinary tract[J]. World J Urol, 2012, 30(1): 51-57.
[8]	Tunney MM, Keane PF, Jones DS, et al. Comparative assessment of ureteral stent biomaterial encrustation[J]. Biomaterials, 1996, 17(15): 1541-1546.
[9]	Shabeena KS, Bhargava R, Manzoor MAP, et al. Characteristics of bacterial colonization after indwelling double-J ureteral stents for different time duration[J]. Urol Ann, 2018, 10(1): 71-75.
[10]	Szell T, Dressler FF, Goelz H, et al. In vitro effects of a novel coating agent on bacterial biofilm development on ureteral stents[J]. J Endourol, 2019, 33(3): 225-231.
[11]	Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement[J]. PLoS Med, 2009, 6(7): e1000097.
[12]	Minardi D, Montanari MP, Tili E, et al. Effects of fluoroquinolones on bacterial adhesion and on preformed biofilm of strains isolated from urinary double J stents[J]. J Chemother, 2008, 20(2): 195-201.
[13]	Torrecilla C, Fernández-Concha J, Cansino JR, et al. Reduction of ureteral stent encrustation by modulating the urine pH and inhibiting the crystal film with a new oral composition: a multicenter, placebo controlled, double blind, randomized clinical trial[J]. BMC Urol, 2020, 20(1): 65.
[14]	Rendina D, De Filippo G, D'Elia L, et al. Metabolic syndrome and nephrolithiasis: a systematic review and meta-analysis of the scientific evidence[J]. J Nephrol, 2014, 27(4): 371-376.
[15]	Wong YV, Cook P, Somani BK. The association of metabolic syndrome and urolithiasis[J]. Int J Endocrinol, 2015, 2015: 570674.
[16]	Itoh Y, Yasui T, Okada A,et al. Preventive effects of green tea on renal stone formation and the role of oxidative stress in nephrolithiasis[J]. J Urol, 2005, 173(1): 271-275.
[17]	Hnow R, Gu K, Hesse A, et al. Oxalate content of green tea of different origin, quality, preparation and time of harvest[J]. Urological Research, 2010, 38(5): 377-381.
[18]	Nasir SJ. The mineralogy and chemistry of urinary stones from the united arab emirates[J]. Qatar Univ Sci, 1999, 18: 189-202.
[19]	Wiseman O, Ventimiglia E, Doizi S, et al. Effects of silicone hydrocoated double loop ureteral stent on symptoms and quality of life in patients undergoing flexible ureteroscopy for kidney stone: a randomized multicenter clinical study[J]. J Urol, 2020, 204(4): 769-777.
[20]	Lamb AD, Vowler SL, Johnston R, et al. Meta-analysis showing the beneficial effect of a-blockers on ureteric stent discomfort[J]. BJU Int, 2011, 108(11): 1894-1902.
[21]	Park SC, Jung SW, Lee JW, et al. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms[J]. J Endourol, 2009, 23(11): 1913-1917.
[22]	Robert M, Boularan AM, El Sandid M, et al. Double-J ureteric stent encrustations: clinical study on crystal formation on polyurethane stents[J]. Urol Int, 1997, 58(2): 100-104.
[23]	Kawahara T, Ito H, Terao H, et al. Ureteral stent encrustation, incrustation, and coloringmorbidity related to indwelling times[J]. J Endourol, 2012, 26(2): 178182.
[24]	Tunney MM, Keane PF, Jones DS, et al. Comparative assessment of ureteral stent biomaterial encrustation[J]. Biomaterials, 1996, 17(15): 1541-1546.
[25]	Zhang Y, He J, Chen H, et al. A new hydrophilic biodegradable ureteral stent restrain encrustation both in vitro and in vivo[J]. J Biomater Appl, 2021, 35(6): 720-731.
[26]	Rouprêt M, Daudon M, Hupertan V, et al. Can ureteral stent encrustation analysis predict urinary stone composition?[J]. Urology, 2005, 66(2): 246-251.
[27]	章又云，李恭会. 输尿管支架管石痂与原发结石成分的对比及成因分析[J]. 中华医学杂志, 2020, 100(14): 1084-1086.
[28]	Zhang D, Li S, Zhang Z, et al. Urinary stone composition analysis and clinical characterization of 1520 patients in central China[J]. Sci Rep, 2021, 11(1): 6467.

组别	例数	性别(例)		结石手术史(例)		腰痛(例)		代谢综合征(例)		手术方式(例)		结石部位(例)			结石清除(例)		肾积水(例)
组别	例数	男	女	有	无	有	无	有	无	经皮肾镜	输尿管镜	肾	输尿管	肾和输尿管	是	否	有	无
结痂组	80	56	24	41	39	64	16	66	14	31	49	30	15	35	51	29	39	41
未结痂组	80	50	30	18	62	16	64	44	36	43	37	40	20	20	63	71	45	35
P值		0.692		0.033		<0.001		0.012		0.0187		0.790			0.017		0.489
组别	喜饮茶(例)		饮食习惯		血尿		术前泌尿系感染控制		尿培养		年龄[岁，(±s)]	肾小球滤过率[ml/min，(±s)]	肌酐[μmol/L，(±s)]	尿pH(±s)	口服抗生素时间[d，(±s)]
组别	是	否	偏荤	偏素	有	无	尚可	不佳	阳性	阴性	年龄[岁，(±s)]	肾小球滤过率[ml/min，(±s)]	肌酐[μmol/L，(±s)]	尿pH(±s)	口服抗生素时间[d，(±s)]
结痂组	47	33	36	44	28	52	51	29	25	55	50±13	91±30	104±62	6.3±0.6	7.9±2.0
未结痂组	27	53	17	63	12	68	50	30	24	56	51±13	89±31	103±87	5.8±0.5	7.8±2.1
P值	0.009		0.048		0.207		0.472		0.931		0.350	0.784	0.291	<0.001	0.495

组别	例数	性别(例)		结石手术史(例)		腰痛(例)		代谢综合征(例)		手术方式(例)		结石部位(例)			结石清除(例)		肾积水(例)
组别	例数	男	女	有	无	有	无	有	无	经皮肾镜	输尿管镜	肾	输尿管	肾和输尿管	是	否	有	无
结痂组	80	56	24	41	39	64	16	66	14	31	49	30	15	35	51	29	39	41
未结痂组	80	50	30	18	62	16	64	44	36	43	37	40	20	20	63	71	45	35
P值		0.692		0.033		<0.001		0.012		0.0187		0.790			0.017		0.489
组别	喜饮茶(例)		饮食习惯		血尿		术前泌尿系感染控制		尿培养		年龄[岁，(±s)]	肾小球滤过率[ml/min，(±s)]	肌酐[μmol/L，(±s)]	尿pH(±s)	口服抗生素时间[d，(±s)]
组别	是	否	偏荤	偏素	有	无	尚可	不佳	阳性	阴性	年龄[岁，(±s)]	肾小球滤过率[ml/min，(±s)]	肌酐[μmol/L，(±s)]	尿pH(±s)	口服抗生素时间[d，(±s)]
结痂组	47	33	36	44	28	52	51	29	25	55	50±13	91±30	104±62	6.3±0.6	7.9±2.0
未结痂组	27	53	17	63	12	68	50	30	24	56	51±13	89±31	103±87	5.8±0.5	7.8±2.1
P值	0.009		0.048		0.207		0.472		0.931		0.350	0.784	0.291	<0.001	0.495

指标	OR值	95%CI值
结石手术史	2.759	1.088~6.997
腰痛	18.7770	07.224~48.804
代谢综合征	3.561	1.318~9.625
结石清除	0.310	0.118~0.811
喜饮茶	3.429	1.361~8.637
饮食偏荤	2.652	1.008~6.974
尿pH<6	0.192	0.096~0.385

指标	OR值	95%CI值
结石手术史	2.759	1.088~6.997
腰痛	18.7770	07.224~48.804
代谢综合征	3.561	1.318~9.625
结石清除	0.310	0.118~0.811
喜饮茶	3.429	1.361~8.637
饮食偏荤	2.652	1.008~6.974
尿pH<6	0.192	0.096~0.385

组别	例数	性别(例)		结石手术史(例)		代谢综合征(例)		结石清除(例)		肾积水情况(例)		术前泌尿道感染控制情况(例)
组别	例数	男	女	有	无	有	无	已清除	未清除	有积水	无积水	尚可	不佳
相同	57	40	17	26	31	48	9	32	25	26	31	35	22
不相同	23	16	07	15	08	18	5	12	11	13	10	16	07
P值		0.957		0.112		0.526		0.747		0.377		0.492
组别	尿培养(例)		喜饮茶(例)		饮食习惯(例)		年龄[岁，(±s)]	肾小球滤过率[ml/min，(±s)]	肌酐[μmol/L，(±s)]	尿pH(±s)	口服抗生素时间[d，(±s)]
组别	阳性	阴性	是	否	偏荤	偏素	年龄[岁，(±s)]	肾小球滤过率[ml/min，(±s)]	肌酐[μmol/L，(±s)]	尿pH(±s)	口服抗生素时间[d，(±s)]
相同	18	39	33	24	28	29	51±12	91±29	104±64	6.2±0.6	7.9±1.9
不相同	07	16	14	09	08	15	46±16	89±32	105.±58	6.5±0.5	7.8±2.4
P值	0.920		0.807		0.243		0.113	0.807	0.943	0.065	0.892

Please choose a citation manager

Content to export